Results 31 to 40 of about 26,674 (238)

A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration : the Be-Raise study [PDF]

, 2016
Objectives : Biological treatment of rheumatoid arthritis (RA) is one of the cornerstones of current treatment strategies for the disease. Surprisingly little information exists on whether the route of administration affects patients' treatment ...
Bert Vander Cruyssen, Dirk Elewaut, Herman Mielants, Jan Lenaerts, null null, Patrick Durez, René Westhovens, Sophie De Mits   +7 more
core   +4 more sources

Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis

Scientific Reports, 2023
HLA-DRB1 shared epitope risk alleles are the strongest genetic risk factors for rheumatoid arthritis (RA) and potential biomarkers for treatment response to biological disease-modifying antirheumatic drugs (bDMARDs).
M. Inoue, Y. Nagafuchi, M. Ota, H. Tsuchiya, S. Tateishi, Hiroko Kanda, K. Fujio   +6 more
semanticscholar   +1 more source

New insights into the impact of neuro-inflammation in rheumatoid arthritis. [PDF]

, 2014
Rheumatoid arthritis (RA) is considered to be, in many respects, an archetypal autoimmune disease that causes activation of pro-inflammatory pathways resulting in joint and systemic inflammation.
Akasbi, Alten, Askling, Axford, Barrick, Bean, Bekkelund, Bongartz, Burmester, Burmester, Capellino, Cheng, Chiu, Chou, Combs, De Almeida, De Rycke, Detrait, Diamond, Doran, Doran, Emmer, Fayed, Feldmann, Firestein, Franklyn A. Howe, Germano, Gregersen, Gussew, Hamed, Harris, Ho, Hull, Hunter, Inan, Jacobs, Kaltsonoudis, Keane, Keystone, King, Klareskog, Lauvsnes, Lee, Leombruno, Lipsky, Listing, MacGregor, Mahdi, Malaviya, Markenson, McInnes, Medeiros, Mellor, Meseguer, Mikuls, Morris, Nadeau, Ni Mhuircheartaigh, Nicholas R. Fuggle, Nidhi Sofat, Nishioku, Norheim, O'Callaghan, Ogawa, Panayi, Parks, Rachel L. Allen, Ramiro, Rech, Rosenblum, Salliot, Salmon-Ceron, Scher, Schoels, Schweinhardt, Scott, Senaldi, Serrats, Skelly, Smolen, Sokka, Steens, Strangfeld, Symmons, Taylor, Teeling, Thomson, Tracey, Tubach, Upadhyay, van der Woude, van Heemst, van Vollenhoven, Vincent, Wallis, Wartolowska, Wegner, Wellcome Trust Case Control Consortium., Wendler, Weyand, Wolfe, Woolf, Zivadinov   +102 more
core   +2 more sources

Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy

Arthritis & Rheumatology, 2023
This open‐label, 24‐week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (DM).
R. Curiel, William Nguyen, Gulnara Mamyrova, Derek Jones, A. Ehrlich, Kathleen A. Brindle, Shahriar Haji-Momenian, R. Sheets, Hanna Kim, O. Jones, L. Rider   +10 more
semanticscholar   +1 more source

T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis

Arthritis Research & Therapy, 2018
Background We aimed to investigate the efficacy of abatacept in preclinical mouse models of digestive involvement, pulmonary fibrosis, and related pulmonary hypertension (PH), mimicking internal organ involvement in systemic sclerosis (SSc).
Gonçalo Boleto, Christophe Guignabert, Sonia Pezet, Anne Cauvet, Jérémy Sadoine, Ly Tu, Carole Nicco, Camille Gobeaux, Frédéric Batteux, Yannick Allanore, Jérôme Avouac   +10 more
doaj   +1 more source

an interim analysis from the observational, prospective ACTION study [PDF]

, 2015
Background The emergence of new therapies for the treatment of rheumatoid arthritis (RA), the paucity of head-to-head studies, and the heterogeneous nature of responses to current biologics highlight the need for the identification of prognostic factors ...
Alten, Rieke, Bars, Manuela Le, Bensen, William G., Burmester, Gerd R., Chartier, Melanie, Galeazzi, Mauro, Lorenz, Hanns-Martin, Nurmohamed, Michael T., Nüßlein, Hubert G., Pavelka, Karel, Peter, Hans-Hartmut, Poncet, Coralie, Rauch, Christiane   +12 more
core   +1 more source

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Journal for ImmunoTherapy of Cancer, 2022
Immune-checkpoint inhibitors (ICI) have revolutionized cancer therapy but are associated with infrequent but lethal myocarditis, for which management remains uncertain.
L. Nguyen, M. Bretagne, J. Arrondeau, N. Zahr, S. Ederhy, B. Abbar, Bruno Pinna, Y. Allenbach, J. Mira, J. Moslehi, M. Rosenzwajg, J. Salem   +11 more
semanticscholar   +1 more source

Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis.

PLoS ONE, 2020
ObjectivesAbatacept acts as a competitive inhibitor of the CD28/(CD80/86) costimulation signal required for T cell activation. Mechanisms of action of abatacept have not been fully investigated. The objective of this study was to provide detailed insight
Céline Derambure, Gaelle Dzangue-Tchoupou, Maria Antonietta D'Agostino, Thierry Lequerré, Olivier Vittecoq   +4 more
doaj   +1 more source

A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease

InflammoPharmacology, 2022
To examine the effectiveness of Janus-kinase inhibitors (JAKis) or abatacept (ABA) in patients with rheumatoid arthritis-interstitial lung disease (RA-ILD).
M. Tardella, M. Di Carlo, M. Carotti, L. Ceccarelli, A. Giovagnoni, F. Salaffi   +5 more
semanticscholar   +1 more source